Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: RCR002
MIFTS: 32

Recurrent Hypersomnia

Categories: Mental diseases, Neuronal diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Recurrent Hypersomnia

About this section

MalaCards integrated aliases for Recurrent Hypersomnia:

IMPROVED
Name: Recurrent Hypersomnia 11 14
Disorders of Excessive Somnolence 43
Primary Recurrent Hypersomnia 11
Hypersomnia, Recurrent 71
Hypersomnia Recurrent 53

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:8619
ICD9CM 34 327.13
MeSH 43 D006970
SNOMED-CT 68 426451004
ICD10 31 G47.1
UMLS 71 C0751226
Sources

Summaries for Recurrent Hypersomnia

About this section

Disease Ontology: 11 A sleep disorder that involves recurring bouts of excessive amounts of sleepiness.

MalaCards based summary: Recurrent Hypersomnia, also known as disorders of excessive somnolence, is related to hypersomnia and idiopathic hypersomnia. An important gene associated with Recurrent Hypersomnia is HCRT (Hypocretin Neuropeptide Precursor), and among its related pathways/superpathways is Orexin and neuropeptides FF and QRFP bind to their respective receptors. The drugs Modafinil and Selegiline have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and heart, and related phenotypes are nervous system and behavior/neurological
Sources

Related Diseases for Recurrent Hypersomnia

About this section

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Recurrent Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Related Disease Score Top Affiliating Genes
1 hypersomnia 31.2 HLA-DQB1 HCRT
2 idiopathic hypersomnia 31.2 HLA-DQB1 HCRT
3 narcolepsy 1 30.2 P2RY11 HLA-DQB1 HCRT
4 rem sleep behavior disorder 29.9 IGLON5 HCRT
5 narcolepsy 29.3 P2RY11 HLA-DQB1 HCRTR2 HCRT
6 migraine with or without aura 1 29.2 HRH3 HCRTR2 HCRT
7 kleine-levin hibernation syndrome 29.1 TRANK1 TOR1B PNMA2 P2RY11 LMOD3 LGI1
8 sleep disorder 29.0 IGLON5 HRH3 HLA-DQB1 HCRTR2 HCRT
9 cranioectodermal dysplasia 10.4
10 narcolepsy 2 10.2 HLA-DQB1 HCRT
11 central sleep apnea 10.1 IGLON5 HCRT
12 autoimmune disease 10.1
13 oculodentodigital dysplasia 10.1
14 tatton-brown-rahman syndrome 10.1
15 guillain-barre syndrome 10.1 HLA-DQB1 HCRT
16 apnea, obstructive sleep 10.0 IGLON5 HCRT
17 sleep apnea 10.0
18 encephalopathy 10.0
19 postinfectious encephalitis 10.0 PNMA2 LGI1
20 akinetic mutism 10.0 PNMA2 LGI1
21 neurosarcoidosis 10.0 PNMA2 LGI1
22 gummatous syphilis 10.0 PNMA2 LGI1
23 chorea gravidarum 10.0 LGI1 IGLON5
24 meningovascular neurosyphilis 10.0 PNMA2 LGI1
25 miller fisher syndrome 10.0 PNMA2 LGI1
26 neuromuscular junction disease 10.0 PNMA2 LGI1
27 headache 10.0 HLA-DQB1 HCRTR2
28 autoimmune neuropathy 10.0 LGI1 IGLON5
29 advanced sleep phase syndrome 10.0 HCRTR2 HCRT
30 periodic limb movement disorder 10.0 HLA-DQB1 HCRTR2 HCRT
31 viral encephalitis 10.0 PNMA2 LGI1
32 demyelinating polyneuropathy 9.9 LGI1 IGLON5
33 anterograde amnesia 9.9 PNMA2 LGI1 HCRT
34 pervasive developmental disorder 9.9
35 autism spectrum disorder 9.9
36 migraine with aura 9.9
37 brain cancer 9.9
38 hepatic encephalopathy 9.9
39 endogenous depression 9.9
40 status epilepticus 9.9
41 post-traumatic stress disorder 9.9
42 bipolar disorder 9.9
43 mood disorder 9.9
44 migraine with brainstem aura 9.9
45 traumatic brain injury 9.9
46 rare pervasive developmental disorder 9.9
47 neuromyelitis optica 9.9 HLA-DQB1 HCRT
48 thymus gland disease 9.8 PNMA2 LGI1
49 autoimmune epilepsy 9.8 PNMA2 LGI1 IGLON5
50 la crosse encephalitis 9.8 PNMA2 LGI1 IGLON5

Graphical network of the top 20 diseases related to Recurrent Hypersomnia:



Diseases related to Recurrent Hypersomnia
Sources

Symptoms & Phenotypes for Recurrent Hypersomnia

About this section

MGI Mouse Phenotypes related to Recurrent Hypersomnia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.5 HCRT HCRTR2 HLA-DQB1 HRH3 LGI1 LMOD3
2 behavior/neurological MP:0005386 9.23 HCRT HCRTR2 HLA-DQB1 HRH3 LGI1 LMOD3
Sources

Drugs & Therapeutics for Recurrent Hypersomnia

About this section

Drugs for Recurrent Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
2
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9, 14611-52-0 5195 26757
3
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
4
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
5 Central Nervous System Stimulants Phase 4
6 Hormones Phase 4
7 Monoamine Oxidase Inhibitors Phase 4
8 Antiparkinson Agents Phase 4
9 Neuroprotective Agents Phase 4
10 Dermatologic Agents Phase 4
11 glucocorticoids Phase 4
12 Adrenergic Agonists Phase 4
13 Bronchodilator Agents Phase 4
14 Hormone Antagonists Phase 4
15 Xhance Phase 4
16
Salmeterol Xinafoate Phase 4 94749-08-3
17 Fluticasone-Salmeterol Drug Combination Phase 4
18 Respiratory System Agents Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Anti-Asthmatic Agents Phase 4
21 Anti-Allergic Agents Phase 4
22 Adrenergic beta-Agonists Phase 4
23 Neurotransmitter Agents Phase 4
24 Nicotinic Agonists Phase 4
25 Cholinergic Agents Phase 4
26
Sodium oxybate Approved Phase 3 502-85-2 23663870
27
Caffeine Approved Phase 2, Phase 3 58-08-2 2519
28
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2 23431961
29
Esreboxetine Approved, Experimental, Investigational Phase 3 98769-81-4, 98819-76-2, 71620-89-8 65856
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
31 Phosphodiesterase Inhibitors Phase 2, Phase 3
32 Adrenergic Agents Phase 3
33 Antidepressive Agents Phase 3
34 Psychotropic Drugs Phase 3
35 Citrate Phase 2, Phase 3
36
Flecainide Approved, Withdrawn Phase 2 54143-55-4 3356
37
Mirtazapine Approved Phase 2 85650-52-8, 61337-67-5 4205
38
Mazindol Approved, Investigational Phase 2 22232-71-9 4020
39
Clarithromycin Approved Phase 2 81103-11-9 84029
40
Dextroamphetamine Approved, Illicit, Investigational Phase 2 51-64-9, 300-62-9 5826 3007
41
Pentetrazol Experimental Phase 2 54-95-5
42 Convulsants Phase 2
43 GABA Modulators Phase 1, Phase 2
44 Antidotes Phase 1, Phase 2
45 Adrenergic Antagonists Phase 2
46 Adrenergic alpha-Antagonists Phase 2
47 Serotonin 5-HT3 Receptor Antagonists Phase 2
48 Histamine H1 Antagonists Phase 2
49 Histamine Antagonists Phase 2
50 Anti-Anxiety Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study Unknown status NCT02385656 Phase 4 Modafinil
2 A Phase 4, Open-Label, Single-Dose Study to Evaluate Sunosi® (Solriamfetol) Pharmacokinetics in Breast Milk and Plasma of Healthy Postpartum Women Following Oral Administration of Sunosi® Completed NCT05008341 Phase 4 Solriamfetol 150 mg Oral Tablet
3 A Multi-center, Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease Completed NCT04870372 Phase 4 Selegiline
4 TITLE: Double-blinded, Double-dummy, Study Comparing Fluticasone-salmeterol to Placebo in Patients With COPD and Associated Poor Sleep or Daytime Somnolence. Completed NCT00731770 Phase 4 Advair 250;Placebo- matched;Placebo;Advair 250 - matched
5 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder Completed NCT01080807 Phase 4 Armodafinil;Matching Placebo
6 Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function Completed NCT04789174 Phase 4 Solriamfetol;Placebo
7 Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Completed NCT00711516 Phase 4 Armodafinil;Placebo
8 Effect of CPAP on Arterial Hypertension and Cardiovascular Morbi-Mortality in Patients With Sleep Apnea and Without Daytime Sleepiness Completed NCT00127348 Phase 4
9 Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder Recruiting NCT04788953 Phase 4 Solriamfetol Oral Tablet;Placebo
10 Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study Terminated NCT02473562 Phase 4 Varenicline;Placebo (for varenicline)
11 Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1 Completed NCT01421992 Phase 2, Phase 3 Methylphenidate;Placebo
12 An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up) Completed NCT01399606 Phase 3 BF2.649
13 A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension Completed NCT03533114 Phase 3 JZP-258;Placebo Oral Solution
14 Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy Completed NCT01067235 Phase 3 BF2.649;BF2.649 add on Modafinil
15 A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase Completed NCT01036139 Phase 3 BF2.649 (pitolisant)
16 A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3 Armodafinil
17 Caffeine for Excessive Daytime Somnolence in Parkinson's Disease Completed NCT00459420 Phase 2, Phase 3 Caffeine 100-200 mg BID;placebo
18 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil With Placebo in Treatment of Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3 Xyrem;Xyrem Placebo;Modafinil at established dose;Modafinil (Placebo)
19 Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness Completed NCT02739568 Phase 3 Pitolisant (BF2.649);Placebo
20 A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 mg) as Treatment for Adults With Excessive Sleepiness Associated With Chronic Shift Work Sleep Disorder Completed NCT00080288 Phase 3 Armodafinil 150 mg/day;Placebo
21 BF2.649 in Patients With Obstructive Sleep Apnea Syndrome (OSA) and Treated by Nasal Continuous Positive Airway Pressure (nCPAP), But Still Complaining of Excessive Daytime Sleepiness (EDS) Completed NCT01071876 Phase 3 BF2.649;Placebo
22 Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01067222 Phase 3 BF2.649;Modafinil;Placebo
23 A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase Completed NCT01066442 Phase 3 BF2.649 (Pitolisant)
24 Efficacy and Safety of BF2.649 in Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea (OSA) Refusing the Nasal Continuous Positive Airway Pressure (nCPAP) Therapy Completed NCT01072968 Phase 3 BF2.649;Placebo
25 A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia Completed NCT02151253 Phase 2, Phase 3 Armodafinil;Placebo
26 A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period) Completed NCT00228553 Phase 3 Armodafinil 100 to 250 mg/day
27 A 3-Day, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Armodafinil Treatment (50 and 150 mg/Day) in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder Completed NCT00758498 Phase 3 armodafinil;placebo
28 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Completed NCT03682185 Phase 3
29 A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy Completed NCT02720744 Phase 3 FT218;Placebo
30 A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy. Completed NCT01800045 Phase 3 Pitolisant;Placebo
31 Randomized, Double-blind, Placebo and Comparator-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01638403 Phase 3 BF2.649;Vigil;palcebo
32 A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia Recruiting NCT03597555 Phase 2, Phase 3 Sodium Oxybate Oral Solution 500 MG/ML;Placebos
33 A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia Recruiting NCT05156047 Phase 3 Pitolisant Oral Tablet;Placebo oral tablet
34 A Randomized, Double-Blind, Placebo-Controlled, Multi- Center Study to Assess the Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy Recruiting NCT05059223 Phase 3 AXS-12 (reboxetine);Placebo
35 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Recruiting NCT05223166 Phase 3 Pitolisant;Placebo oral tablet
36 Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR Active, not recruiting NCT04451668 Phase 3 FT218
37 A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy Enrolling by invitation NCT05113745 Phase 3 AXS-12 (reboxetine);Placebo
38 An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 Enrolling by invitation NCT05458128 Phase 3 pitolisant
39 Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness Withdrawn NCT02978651 Phase 3 Pitolisant (BF2.649);Placebo Oral Tablet
40 A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia Unknown status NCT03542851 Phase 2 Pentetrazol (PTZ);Placebo oral capsule
41 A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors Completed NCT01183312 Phase 1, Phase 2 Flumazenil
42 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
43 Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness Completed NCT03624920 Phase 2 THN102 Dosage A;THN102 Dosage B;THN102 Dosage C
44 A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy Completed NCT01681121 Phase 2 ADX-N05;Placebo
45 Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder Completed NCT00385437 Phase 2 Mirtazapine Treatment
46 Randomized, Dose-finding Study of BF 2.649 5, 10 20 and 40 mg/d in Comparison to Placebo in Excessive Daytime Sleepiness in Parkinson's Disease Patients (PD) Completed NCT00642928 Phase 2 Placebo;BF 2.649 5 mg;BF 2.649 10 mg;BF 2.649 20 mg;BF 2.649 40 mg
47 A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease Completed NCT00641186 Phase 2 sodium oxybate
48 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Hypnotic Efficacy of EVT 201 in Elderly Patient With Daytime Sleepiness Completed NCT00401284 Phase 2 EVT 201
49 A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Narcolepsy Completed NCT02806908 Phase 2 JZP-110;Placebo
50 A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Obstructive Sleep Apnea Completed NCT02806895 Phase 2 JZP-110;Placebo

Search NIH Clinical Center for Recurrent Hypersomnia

Cochrane evidence based reviews: disorders of excessive somnolence

Sources

Genetic Tests for Recurrent Hypersomnia

About this section
Sources

Anatomical Context for Recurrent Hypersomnia

About this section

Organs/tissues related to Recurrent Hypersomnia:

MalaCards : Brain, Breast, Heart, Thalamus
Sources

Publications for Recurrent Hypersomnia

About this section

Articles related to Recurrent Hypersomnia:

(show top 50) (show all 51)
# Title Authors PMID Year
1
A patient with anti-aquaporin 4 antibody who presented with recurrent hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic lesions. 53 62
18226957 2009
2
Different circadian rest-active rhythms in Kleine-Levin syndrome: a prospective and case-control study. 62
33851710 2021
3
[Tularaemia in two patients referred on suspicion of cancer mammae and cancer occulta]. 62
33000721 2020
4
Usefulness of brain SPECT imaging in the study of recurrent hypersomnia: Kleine-Levin syndrome. 62
28869046 2019
5
Kleine-Levin syndrome: A neuropsychiatric disorder. 62
29606318 2018
6
Recurrent Hypersomnia and Autonomic Dysregulation in Posttraumatic Stress Disorder. 62
29117891 2017
7
A Case of Recurrent Hypersomnia With Autonomic Dysfunction. 62
28633719 2017
8
Migraine with brainstem aura presenting as recurrent hypersomnia (Kleine-Levin syndrome). 62
27343267 2016
9
Kleine-Levin Syndrome. 62
27137943 2016
10
Recurrent hypersomnia in an 18-year old boy: CSF hypocretin level and MSLT findings. 62
26323648 2016
11
Menstruation-Related Hypersomnia Treated with Hormonal Contraception: Case Report and Review of Literature. 62
26932284 2016
12
Do the Symptoms of Kleine-Levin Syndrome Correlate With the Hypometabolism of the Thalamus on FDG PET? 62
26562572 2016
13
Circadian disruption: New clinical perspective of disease pathology and basis for chronotherapeutic intervention. 62
27308960 2016
14
Recurrent hypersomnia: Report of medication-responsive cases. 62
26483951 2015
15
Narcolepsy with and without cataplexy, idiopathic hypersomnia with and without long sleep time: a cluster analysis. 62
25576137 2015
16
Misdiagnosis of menstruation-related recurrent hypersomnia as epilepsy in a patient with generalized epileptic discharges. 62
25878739 2015
17
Treatment of Kleine-Levin syndrome with acetazolamide. 62
25317098 2014
18
Kleine-Levin syndrome: a case report and review of literature. 62
24630285 2014
19
Kleine-Levin syndrome: a review. 62
24470783 2014
20
[The Kleine-Levin syndrome: new aspects of a rare disease]. 62
23942582 2013
21
Recurrent hypersomnia following traumatic brain injury. 62
23499199 2013
22
Diagnosis and management of central hypersomnias. 62
22973425 2012
23
Recurrent hypersomnia due to occult hepatic encephalopathy. 62
22154356 2012
24
A rapid screening test for depression in junior high school children. 62
21872817 2011
25
Recurrent hypersomnia: a review of 339 cases. 62
20970360 2011
26
Familial recurrent hypersomnia: two siblings with Kleine-Levin syndrome and menstrual-related hypersomnia. 62
20404354 2010
27
[A case of recurrent hypersomnia with excellent response to lithium carbonate]. 62
21061548 2010
28
Non-convulsive status epilepticus presenting as recurrent hypersomnia. 62
20463123 2010
29
Gabapentin for Kleine-Levin syndrome. 62
19571456 2009
30
Polysomnography in Kleine-Levin syndrome. 62
18316691 2008
31
Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. 62
18246980 2007
32
Hypersomnias of central origin. 62
16963696 2006
33
Differential diagnosis in hypersomnia. 62
16522270 2006
34
Hypersomnia. 62
16416710 2005
35
Case study: differences in human Per2 gene expression, body temperature, cortisol, and melatonin parameters in remission and hypersomnia in a patient with recurrent hypersomnia. 62
14535361 2003
36
[Recurrent hypersomnia]. 62
14503208 2003
37
Decreased blood flow of the left thalamus during somnolent episodes in a case of recurrent hypersomnia. 62
12047594 2002
38
Recurrent hyper- and hyposomnia: a new diagnostic entity? Polysomnographic findings and a 30-year follow-up. 62
14592248 2002
39
[Disorders of awakening. Second part: secondary disorders]. 62
11438768 2001
40
Kleine Levin syndrome (KLS) in young females. 62
10875563 2000
41
Prolonged polysomnography in a case with recurrent hypersomnia. 62
9628153 1998
42
[Recurrent hypersomnia]. 62
9503836 1998
43
Recurrent hypersomina: a case report with polysomnographic findings. 62
11847365 1997
44
Treatment of recurrent hypersomnia with methylcobalamin (vitamin B12): a case report. 62
8726119 1995
45
Electrophysiological and immunogenetic findings in recurrent monosymptomatic-type hypersomnia: a study of two unrelated Italian cases. 62
8256576 1993
46
Recurrent hypersomnia in two adolescent males with Asperger's syndrome. 62
1644738 1992
47
[Recurrent hypersomnia caused by acute toluene poisoning]. 62
2361041 1990
48
[Recurrent hypersomnia]. 62
3047832 1988
49
Recurrent hypersomnia secondary to sleep apnea. 62
718480 1978
50
Recurrent hypersomnia secondary to sleep apnea. 62
889488 1977
Sources

Variations for Recurrent Hypersomnia

About this section
Sources

Expression for Recurrent Hypersomnia

About this section
Search GEO for disease gene expression data for Recurrent Hypersomnia.
Sources

Pathways for Recurrent Hypersomnia

About this section

Pathways related to Recurrent Hypersomnia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Orexin and neuropeptides FF and QRFP bind to their respective receptors 66
9.53 HCRTR2 HCRT
Sources

GO Terms for Recurrent Hypersomnia

About this section

Biological processes related to Recurrent Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 feeding behavior GO:0007631 9.13 HCRTR2 HCRT
2 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.1 P2RY11 HCRTR2 HCRT
Sources

Sources for Recurrent Hypersomnia

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....